Article Text

Download PDFPDF

Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort
  1. Geoff Strange1,2,
  2. David Playford3,4,5,
  3. Simon Stewart6,
  4. Jenny A Deague3,4,
  5. Helen Nelson5,
  6. Aaron Kent3,
  7. Eli Gabbay2,3,4,7
  1. 1Monash University, Victoria, Australia
  2. 2Lung Institute of Western Australia, Western Australia, Australia
  3. 3Faculty of Medicine, University of Notre Dame, Fremantle, Western Australia
  4. 4Faculty of Medicine, University of Western Australia, Western Australia, Australia
  5. 5Armadale Health Service, Albany Hwy, Armadale, Western Australia
  6. 6The Baker IDI Heart and Diabetes Institute, Melbourne, Australia
  7. 7Royal Perth Hospital, Perth, Australia
  1. Correspondence to Professor David Playford, Suite 10, Galliers Specialist Centre, 3056 Albany Hwy, Armadale 6112, Western Australia, Australia; dplayford{at}heartswest.com.au

Footnotes

  • Funding DP received an unrestricted research grant from Actelion Pharmaceuticals. No company was involved in the collection, analysis or reporting of these data. All authors contributed to the development, design and review of this manuscript.

  • Competing interests GS receives honoraria from the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ). The PHSANZ receives grant funding from Actelion, Bayer, GSK, Lilly, Novartis and Pfizer Australia. DP has received honoraria for speaking from Actelion and Pfizer Australia. SS, JD, HN, AK have no conflict of interest to declare. EG has received research funds from Actelion, Bayer, GSK and Pfizer Australia. EG has received honoraria for speaking from Actelion, Bayer, GSK and Pfizer. EG in currently a member of the Advisory Boards for Actelion, Eli Lilly, GSK and Pfizer Australia.

  • Ethics approval Ethics approval was provided by University of Notre Dame ethics comittee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding DP received an unrestricted research grant from Actelion Pharmaceuticals. No company was involved in the collection, analysis or reporting of these data. All authors contributed to the development, design and review of this manuscript.

  • Competing interests GS receives honoraria from the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ). The PHSANZ receives grant funding from Actelion, Bayer, GSK, Lilly, Novartis and Pfizer Australia. DP has received honoraria for speaking from Actelion and Pfizer Australia. SS, JD, HN, AK have no conflict of interest to declare. EG has received research funds from Actelion, Bayer, GSK and Pfizer Australia. EG has received honoraria for speaking from Actelion, Bayer, GSK and Pfizer. EG in currently a member of the Advisory Boards for Actelion, Eli Lilly, GSK and Pfizer Australia.

  • Ethics approval Ethics approval was provided by University of Notre Dame ethics comittee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.